1
y .
Introduction 23
Stress cardiomyopathy (SCM), also known as "broken heart syndrome" or 24 takotsubo syndrome, 1; 2 is a condition that captures widespread public interest.
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The cardiomyopathy is distinctive and the precipitating emotional event is 26 typically clearly defined, however the mechanism for the cardiomyopathy and 27 links between the psychological event and the physical illness are not 28 understood. 29 30 Sporadic cases of SCM are estimated to account for 1-5% of acute coronary 31 syndrome presentations. [3] [4] [5] Predominantly the condition occurs in post-32 menopausal women, 6; 7 and because of this, 5-10% of female presentations with 33 suspected acute coronary syndrome are attributed to SCM. [8] [9] [10] [11] Although SCM 34 can be fatal, the symptoms are commonly transient and patients generally have 35 a good prognosis and recover well over a period of days to weeks. 12 In classic 36 descriptions the cardiomyopathy has a typical pattern but a number of variations 37 are now widely recognised and it is increasingly apparent that cases can be 38 quite heterogeneous. 13 39 40 SCM occurring in clusters around the time of major disasters such as 41 earthquakes, floods and bushfires is also well recognised. 6; 14-16 Due to the large 42 impact these events have upon hospital resources and medical infrastructure, it 43 is rare for such clusters of SCM to be studied in any depth. This was made clear 44 in reports from the Great East Japan Earthquake. 17 In the Canterbury (New 45 Zealand) earthquake sequence of 2010 and 2011 the two main events 46 precipitated large case clusters of SCM. [17] [18] [19] [20] [21] [22] Unusually for a major natural disaster, the tertiary hospital in Christchurch continued to function, allowing the 48 collection of a relatively large homogenous cohort of cases which have been 49 followed over several years. [18] [19] [20] [21] [22] [23] Most research around this disorder has focused Page 8 liquid-handling robot (Thermo Fisher Scientific, Inc, Waltham, MA) . DNA was 151 quantified by analysis with the Nanodrop TM (ThermoFisher), and, where 152 appropriate, the Tapestation 4200 system (Agilent Technologies). 153 154
Exome analysis 155
We applied WES to a subset (24 of 28) EqSCM cases. The exome capture and 156 sequencing was carried out in two batches of 12, during 2012-13 (New Zealand Page 12 allele frequency > 3%, and selecting for any present in at least 4/24 EqSCM 251 exomes, identified variants in 131 genes, none of which proved to be convincing 252 on closer analysis. We also carried out ranking of gene variants by predicted 253 functional impact using various approaches. 61; 62; 82 Once again, none of the 254 variants identified in these analyses proved to be significantly enriched amongst 255 our EqSCM exomes. To test for potential involvement of CNVs in SCM, we applied aCGH to all 288 cases. Of the 28 EqSCM cases examined by aCGH, twelve (42%) showed 289 evidence of large, rare heterozygous CNVs classified as being of unclear clinical 290 significance ( Table 2) , meaning that insufficient evidence is available for 291 unequivocal determination of clinical significance. 73 Of these CNVs, seven were 292 deletions and six were duplications. All of the CNVs were different, and there 293 was no physical overlap between the various CNVs. Each of these rare CNVs 294 encompasses one or more genes, or their immediate upstream regulatory 295 regions, and many of the genes included within the CNVs have functions of 296 cardiac relevance. A full list of all CNVs detected in the cohort is presented in 297 Table S1 . 298
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Three cases (EqSCM 01, 06 and 19) harboured deletions very likely to impact 300 genes of high relevance to cardiomyopathy or cardiac function. In EqSCM 01, 301 intragenic deletion of RBFOX1 results in a single copy loss of one exon used by 302 the majority of transcripts predicted for the gene (Figure 1 ). This exon contains 303 the start methionine for the RBFOX1 protein, meaning the gene is most likely 304 rendered non-functional. RBFOX1 is an important RNA-binding protein 305 mediating the incorporation of microexons into many transcripts associated with 306 neurological patterning and tissue development, 85; 86 particularly in the brain, 307 heart and muscles. Intragenic deletions in RBFOX1 have been observed in a 308 range of conditions, including occasional cases with cardiac defects. 87; 88; 89 309 Furthermore, RBFOX1-mediated RNA splicing was also recently shown to be an 310 important regulator of cardiac hypertrophy and heart failure 90 . 311
312
In the second case (EqSCM 06, Figure. 2), a heterozygous deletion 313 encompassed exon 2 and the majority of intron 2 of the Glypican 5 (GPC5) 314 locus. GPC5 encodes a cell surface proteoglycan, which binds to the outer 315 surface of the plasma membrane in the cardiovascular system and displays 316 diverse functions including blood vessel formation after ischemic injury and 317 proliferation of smooth muscle cells during atherogenesis. 91 GPC5 was also 318 implicated by GWAS as a protective locus for sudden cardiac arrest, 92 and other 319 glypicans (GPC3, 4 and 6) have been associated with cardiac dysfunction. 93 320 This case (EqSCM 06) also harbours a duplication on 4q21.21 involving the 321 ANXA3 gene, which encodes a member of the annexin family, annexin A3. 322
Members of this calcium-dependent phospholipid-binding protein family have a 323 range of functions in the regulation of cellular growth and signal transduction Page 15 pathways. Annexin A6 for example is the most abundant annexin expressed in 325 the heart and its overexpression in mice has been shown to cause physiological 326 alterations in contractility leading to dilated cardiomyopathy, while Annexin A6 327 knockout has been found to induce faster changes in Ca2+ transience and 328 increased contractility. 94; 95 Alterations in expression and activity of annexins A5 329 and A7 have also been found to be associated with regulation of Ca2+ handling 330 in the heart. 96 The function of annexin A3 is not fully understood, however it has 331 been shown to play a role in endothelial migration and vascular development. 97 332 333
The third case (EqSCM 19) , contained a deletion at chr13q14.3. This region 334 harbours at least 10 genes (DLEU2, TRIM13, KCNRG, MIR15A, 335 DLEU1, ST13P4, DLEU7, , 336
including several non-coding RNAs (DLEU genes and micro-RNA genes) and a 337 gene (KCNRG) encoding a protein involved in the regulation of voltage-gated 338 potassium channel activity. The micro-RNA genes mir-16-1 and mir-15a in this 339 interval have been implicated in a range of cardiovascular phenotypes, including 340 a role for mir-15a in postnatal mitotic arrest of cardiomyocytes. 98-100 Two further 341 chromosome 13 duplicated CNVs of approximately 150kb were classified as 342 uncertain significance -one involving LINC00346 and ANKRD10 and the other 343 containing ENOX1, postulated to affect vascular development based on 344 zebrafish expression patterns 101 (Table 2) . 345 346 Beyond these three cases, cardiac or relevant neurological impacts appeared 347 likely for many of the other rare CNVs identified in EqSCM cases ( have been reported by the DGV database 105 but none span the genes within this 363 CNV. GPBP1L1 is widely expressed in many tissues, including heart muscle 106 364 and predicted to be involved in transcriptional regulation. TMEM69, a gene of 365 unknown function, is most strongly expressed in heart tissue. 106 IPP is a 366 transcription factor with a 50 amino acid Kelch repeat known to interact with 367 actin, while MAST2 contains a PDZ domain and is another gene highly 368 expressed in heart and skeletal muscle. 106 The protein product of PIK3R3, 369 phosphoinositide-3-kinase regulatory subunit 3, acts downstream of G-protein-370 coupled receptors in cardiac function, 107 and is also a target for isoproterenol, 371 which can trigger SCM-like conditions in humans and rodents. 12; 108-110 372
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Duplication of a long non-coding RNA (LOC101928358), the 3' segment of 374 COL4A5 and the entire IRS4 gene at Xq22.3 (9 probes, 113kb) was identified 375 within case EqSCM 05. IRS4 is an insulin receptor molecule expressed in heart 376 and skeletal muscle cells 111 and other tissues such as brain, kidney and liver. 112 377 Duplication of IRS4 may be of functional significance, although copy number 378 increases on the X chromosome of females may be counteracted to a degree by 379 random X inactivation. Of note is a Genoglyphix Chromosome Aberration 380 Database (GCAD 70 ) case 52414 with a phenotype of low muscle tone, which 381 has an identical duplication at this locus (as well as a 1p33 deletion). With 382 regard to IRS4, Schreyer et al. (2003) 111 found a more restricted tissue 383 distribution than IRS1 and IRS2, in primary human skeletal muscle cells and rat 384 cardiac muscle and isolated cardiomyocytes. Although IRS4 protein function is 385 still relatively unknown, the role of IRS proteins in general, acting as mediators 386 of intracellular signalling from insulin and insulin-like growth factor 1 receptors, 387 implicates IRS4 in cell growth and survival. 113 It is interesting to note that PI 3-388 kinase (PI3K) signalling in HEH293T cells depends on IRS4, and that the IRS 389 proteins relay signals from receptor tyrosine kinases to downstream 390 components of signalling pathways, 111 which we note is a connection with the 391 PIK3R3 gene duplicated in one of our other cases, EqSCM 04. 392 393 EqSCM 10 harboured a 130kb duplication of NLRP7, NLRP2, GP6 and RDH13 394 at 19q13.42. One similar DGV duplication has been seen in this area 395 (nsv1062047 105 ), but otherwise duplicated CNVs are generally much smaller 396 and rare. NLRP2 and NLRP7 are genes that encode members of the NACHT, Page 18 are implicated in the activation of pro-inflammatory caspases. Recessive 399 mutations ininin NLRP2/7 in humans are associated with reproductive 400 disorders. 114 Another gene in this duplicated cluster associated with disease is 401 GP6, a platelet membrane glycoprotein, involved in collagen-induced platelet 402 aggregation and thrombus formation, which is expressed at high levels in heart, 403 kidney and whole blood. 106 A GP6 SNP (c.13254TC) has been implicated in 404 recurrent cardiovascular events and mortality. 115 Another study involving this 405 SNP, 116 found that hormone replacement therapy (HT) reduced the hazard ratio 406 (HR) of CHD) events in patients with the GP6 13254TT genotype by 17% but 407 increased the HR in patients with the TC+CC genotypes by 35% (adjusted 408 interaction P < 0.001). The authors found that in postmenopausal women with 409 established CHD, the GP6 polymorphism, and another in GP1B, were predictors 410 of CHD events and significantly modified the effects of HT on CHD risk. 116 MetaboChip, which is less able to provide a rich dataset of genome-wide SNP 485 genotypes than the chips commonly used for GWAS, and the relatively small 486 cohort of cases available for study. Recruitment of a much larger SCM cohort 487 with a view to a well-powered GWAS with a more extensive genotyping chip 488 would therefore be a worthwhile future goal to more fully explore possible 489 polygenic underpinnings of this disorder. We note the recent publication of a 490 preliminary GWAS on 96 SCM cases and 475 healthy controls, 124 Zealand aCGH case series (5,300 pre-and post-natal tests) reported CNVs in 507
28.3% of these clinically-selected cases. 142 Our observation of a rate of 42% for 508 the EqSCM case series is significantly greater (P < 0.02) than rates for the 509 enriched case cohorts normally referred for clinical aCGH testing [139] [140] [141] [142] . The 510
CNVs detected in EqSCM cases were all different, and there were no physical 511 overlaps between them. This situation is similar to the pattern of CNVs seen in 512 other conditions, including rolandic epilepsies 118 and congenital heart 513 disease. 133; 135; 136 Many of the CNVs we observed are likely to impact genes of 514 potential relevance to physiological processes implicated in SCM. 515
Page 23 homozygous 129kb deletion in this region was associated with Graves's disease 524 and aortic aneurysm. 145 However, several deletions of DOCK8 are recorded in 525 the DGV for unaffected individuals, therefore the CNVs in EqSCM 14 and 28 526 were categorised as TBB (thought to be benign). The approximately160kb 527 duplication in EqSCM 28 was larger than the 44kb deletion in EqSCM 14, and it 528 encompassed a second gene, KANK1. A small number of similar duplications 529 have been recorded in the DGV, and therefore we did not consider this to be 530 pathogenic. However, it is of interest that we see two relatively rare CNVs at this 531 locus in our small EqSCM cohort. 532
533
Of the twelve EqSCM cases with rare CNVs, we consider that three (EqSCM 01, 534 06 and 19) contain CNVs that affect genes of high relevance to cardiomyopathy 535 or cardiac function. The remaining candidate CNVs are also strong candidates 536 with potential functional relevance. In one of our most highly-ranked candidate 537 CNV containing cases (EqSCM 01) a large genomic deletion removes an exon 538 of RBFOX1 which contains the start codon used by the majority of transcripts 539 predicted for the gene. A recent report by Gao et al. (2016) provided strong 540 functional data that would support our hypothesis of this gene's involvement as 541 a susceptibility locus for SCM 90 . Their work with mouse models has shown 542 RBFox1 deficiency in the heart promoted pressure overload-induced heart 543 failure, and induction of RBFox1 over-expression in these murine pressure-544 overload models, substantially attenuated cardiac hypertrophy and pathological 545 manifestations 90 . The haploinsufficiency seen in EqSCM 01 at the RBFOX1 546 locus may, in concert with other environmental or genetic factors, contribute to 547 SCM through reduced global RNA splicing changes in the heart.
Conclusion 549
Beginning with a cohort of 28 SCM cases triggered by two major earthquakes 550 that caused extensive death and damage in Christchurch (New Zealand), we 551 carried out exploratory analyses of three models for genetic predisposition to 552 this disorder. Using WES and Cardio-MetaboChip genotyping analyses we did 553 not detect an obvious role for exonic mutations in a monogenic model, or SNPs 554 in a polygenic model, for SCM risk. However, our analysis of copy number 555 variation in SCM cases revealed a high rate of occurrence of CNV categorised 556 as of uncertain clinical significance. Most of the CNV we detected in SCM cases 557 were rare, or not previously seen (Table 2) . 558 559 These observations lead us to propose that SCM is a copy number variant 560 disorder, whereby haploinsufficiency of genes overlapping deletions or over-561 expression of duplicated genes leads to relatively subtle modification of cardiac 562 or adrenergic physiology, such that these individuals are at increased risk of 563 suffering SCM when exposed to specific environmental triggers. Although no 564 obvious single pathway relationships between the genes affected by these 565
CNVs is apparent, most of the CNVs encompass loci relevant to cardiac 566 function or cardioneuronal development. 567
568
In order to confirm whether SCM predisposition does indeed arise from CNVs, 569
four key areas for future work need to be pursued. First, more widespread 570 analysis is required of CNVs in many SCM cases. This would confirm whether 571 our observation of a high rate of CNV in EqSCM also prevails in sporadic cases, 572 and it will broaden the catalog of affected genes, helping to discern underlying Page 25 signalling networks and physiological processes. In addition, with increasing 574 numbers of cases, physical overlaps between CNVs in different individuals 575 should become apparent, pinpointing key genomic regions for more intensive 576 analysis. Second, the inheritance patterns of these CNVs must be established. It 577 is unclear what proportion are de novo versus inherited from either parent. 578
Third, there is a clear need for detailed physiological and gene expression 579 analyses on appropriate cells, including cardiomyocytes, derived from SCM 580 cases. Given the diversity of CNV seen in our SCM cases, this goal would most 581 effectively be achieved by generation of induced-pluripotent stem cell (iPSC) 582 lines from many patients and appropriate controls. 146; 147 Finally, although our 583 data implicate CNV as a significant genetic factor underlying SCM risk, it would 584 seem wise to pursue an effective GWAS strategy to identify other genetic 585 contributors to SCM and build on the initial study in this area. 124 International 586 initiatives to collate SCM cases 13 should therefore ensure that consented DNA is 587 available to provide appropriately large numbers of well phenotyped cases and 588 controls to facilitate this goal. 589 590 Finally, we hope our observations implicating CNV in this unique case series of 591
EqSCM will stimulate further studies of copy number variation in other SCM 592 cohorts, and lead to an improved understanding of this perplexing and intriguing 593 
